- Home
- EM vs ADAG Comparison
EM vs ADAG Comparison
Compare EM & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EM | ADAG |
|---|---|---|
| Founded | 2017 | 2011 |
| Country | China | China |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 296.7M | 254.4M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | EM | ADAG |
|---|---|---|
| Price | $1.20 | $3.75 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $1.25 | ★ $8.25 |
| AVG Volume (30 Days) | 130.8K | ★ 205.5K |
| Earning Date | 06-02-2026 | 04-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.30 | N/A |
| Revenue Next Year | $5.26 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.01 | $1.44 |
| 52 Week High | $1.46 | $4.75 |
Technical Indicators
Market Signals| Indicator | EM | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 66.07 | 51.48 |
| Support Level | $1.16 | $3.40 |
| Resistance Level | $1.42 | $3.99 |
| Average True Range (ATR) | 0.02 | 0.28 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 73.68 | 80.60 |
Price Performance
Historical ComparisonAbout EM Smart Share Global Limited
Smart Share Global Ltd is a consumer tech company providing mobile device charging services through an extensive online and offline network in China. It provides service through power banks, placed in POIs operated by location partners, such as entertainment venues, restaurants, shopping centers, hotels, transportation hubs, and public spaces. Geographically, the company generates revenue from the PRC. The company has two segments, the mobile device charging segment and the PV business segment. The company generates the majority of its revenue from the mobile device charging segment.
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.